Redesign of NCI Clinical Trials System
The US National Cancer Advisory Board (NCAB) today formally accepted 22 strategic recommendations designed to reshape and enhance the National Cancer Institute's (NCI) clinical trials system.
The recommendations are included in a report "Restructuring the National Cancer Institute Clinical Trials Enterprise." The report was developed by the Clinical Trials Working Group (CTWG), a panel of 40 stakeholders established by NCI Director Dr. Andrew C. von Eschenbach in 2004. NCAB's vote to accept the report sets in motion several major steps to implement the recommendations that were first presented to NCAB in February. The result is a series of initiatives that includes an implementation plan and budget.
CTWG Chair Dr. James H. Doroshow, director of NCI's Division of Cancer Treatment and Diagnosis (DCTD), presented the report to NCAB. "With these steps, we hope to integrate the best of NCI's current clinical trial system into a cross-disciplinary enterprise," said Dr. Doroshow. For a detailed description of the CTWG recommendations go to http://integratedtrials.nci.nih.gov.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
